Pulse Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on February 9, 2022, with the earliest event reported on February 14, 2022. The filing discloses the appointment of a new senior executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and equity awards.
Material Changes and Executive Appointment
The primary material event is the appointment of Kevin Danahy as Chief Commercial Officer, effective February 14, 2022. Key terms of his employment agreement include:
- Base Salary: $395,000 annually.
- Target Bonus: Up to 50% of base salary.
- Equity Award: Options to acquire 300,000 shares of common stock.
- Exercise Price: $6.41 per share (closing price on February 14, 2022).
- Vesting: Subject to time-based and performance-based criteria over four years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The press release regarding this appointment is furnished under Items 5.02 and 8.01 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the vesting schedule details and performance criteria for the 300,000 stock options granted to Mr. Danahy.
- Confirm the impact of this new executive role on the company's commercial strategy and sales pipeline.
- Review the company's 2017 Inducement Equity Incentive Plan to understand the terms governing this award.
- Monitor future filings for any changes to the executive team or additional equity grants.